Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome. A pilot study

A. Piccoli, F. Gastaldon, L. Pillon, M. Mussap, D. Faggian, M. Plebani, A. Borsatti

Research output: Contribution to journalArticlepeer-review

Abstract

To establish the bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome, we compared the effects of the two drugs on both glomerular and tubular functions in 10 adult patients with proteinuria >3.5 gm/day (range, 3.6 to 14 gm/day). A crossover, randomized clinical trial was conducted over a 3-month period (1-week induction with three 500-mg IV methylprednisolone bolus doses, followed by 5 weeks of treatment with 30 mg/day of deflazacort and 5 weeks with 25 mg/day of prednisone). The treatment sequence, deflazacort-prednisone or prednisone-deflazacort, was randomly assigned. After the crossover period, all patients were treated with 30 mg/day of deflazacort for 3 to 6 months, eventually tapering (30 mg every other day for 2 weeks, then 15 mg every other day for 2 weeks) after remission of proteinuria. At the end of the crossover period, a significantly higher rate (80% vs 20%) of partial remission of nephrotic syndrome (ie, proteinuria

Original languageEnglish
Pages (from-to)588-597
Number of pages10
JournalCurrent Therapeutic Research
Volume54
Issue number5
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome. A pilot study'. Together they form a unique fingerprint.

Cite this